FXS6837 for the Treatment for IgAN Patients（Longterm Study）
Starting soon · Phase 2
Conditions studied: Primary IgAN
In brief
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.
Key facts
- Study ID
- NCT07750665
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- People needed
- 60
- Starts
- 2026-09-30
- Expected to finish
- 2030-01-04
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Peking University First Hospital — Beijing, Beijing Municipality, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.